Home / Publications / Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity

Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity

Daniil Viktorovich Spector 1
Daniil Viktorovich Spector
Roman Aleksandrovich Akasov 2, 3
Roman Aleksandrovich Akasov
Elena Kimovna Beloglazkina 1
Elena Kimovna Beloglazkina
Olga Olegovna Krasnovskaya 1
Olga Olegovna Krasnovskaya
2 Moscow Pedagogical State University, 129226 Moscow, Russian Federation
3 I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russian Federation
Published 2025-03-31
CommunicationVolume 35, Issue 3, 282-284
0
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Spector D. V. et al. Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity // Mendeleev Communications. 2025. Vol. 35. No. 3. pp. 282-284.
GOST all authors (up to 50) Copy
Spector D. V., Akasov R. A., Mazur D. M., Roznyatovsky V. A., Grishin Y. K., Beloglazkina E. K., Krasnovskaya O. O. Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity // Mendeleev Communications. 2025. Vol. 35. No. 3. pp. 282-284.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.71267/mencom.7643
UR - https://mendcomm.colab.ws/publications/10.71267/mencom.7643
TI - Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity
T2 - Mendeleev Communications
AU - Spector, Daniil Viktorovich
AU - Akasov, Roman Aleksandrovich
AU - Mazur, Dmitrii Mikhailovich
AU - Roznyatovsky, Vitaly A
AU - Grishin, Yuri Konstantinovich
AU - Beloglazkina, Elena Kimovna
AU - Krasnovskaya, Olga Olegovna
PY - 2025
DA - 2025/03/31
PB - Mendeleev Communications
SP - 282-284
IS - 3
VL - 35
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Spector,
author = {Daniil Viktorovich Spector and Roman Aleksandrovich Akasov and Dmitrii Mikhailovich Mazur and Vitaly A Roznyatovsky and Yuri Konstantinovich Grishin and Elena Kimovna Beloglazkina and Olga Olegovna Krasnovskaya},
title = {Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity},
journal = {Mendeleev Communications},
year = {2025},
volume = {35},
publisher = {Mendeleev Communications},
month = {Mar},
url = {https://mendcomm.colab.ws/publications/10.71267/mencom.7643},
number = {3},
pages = {282--284},
doi = {10.71267/mencom.7643}
}
MLA
Cite this
MLA Copy
Spector, Daniil Viktorovich, et al. “Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity.” Mendeleev Communications, vol. 35, no. 3, Mar. 2025, pp. 282-284. https://mendcomm.colab.ws/publications/10.71267/mencom.7643.

Keywords

cisplatin
controlled release
optical visualization
PDT
platinum(IV) prodrug
riboflavin

Abstract

Novel triple-action photoactivatable PtIV prodrugs were obtained by modification of Riboplatin, a cisplatin-based prodrug bearing tetraacetylriboflavin in axial position. The modification involved incorporation of either Naproxen or albumin vector maleimide residues onto the second axial position of Riboplatin. The PtIV prodrugs thus obtained possess improved pharmacokinetic, biological and photoactivating properties.

Funders

Russian Science Foundation
22-15-00182

References

1.
Pt(Iv) prodrugs with nsaids as axial ligands
Spector D., Krasnovskaya O., Pavlov K., Erofeev A., Gorelkin P., Beloglazkina E., Majouga A.
International Journal of Molecular Sciences, 2021
2.
Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX‐2 and PD‐L1
Jin S., Muhammad N., Sun Y., Tan Y., Yuan H., Song D., Guo Z., Wang X.
Angewandte Chemie - International Edition, 2020
3.
Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light
Wang Z., Wang N., Cheng S., Xu K., Deng Z., Chen S., Xu Z., Xie K., Tse M., Shi P., Hirao H., Ko C., Zhu G.
Chem, 2019
4.
Larsen M.T., Kuhlmann M., Hvam M.L., Howard K.A.
Molecular and Cellular Therapies, 2016
6.
Biotin-tagged platinum(iv) complexes as targeted cytostatic agents against breast cancer cells.
Muhammad N., Sadia N., Zhu C., Luo C., Guo Z., Wang X.
Chemical Communications, 2017
8.
The rediscovery of platinum-based cancer therapy
Rottenberg S., Disler C., Perego P.
Nature Reviews Cancer, 2020
9.
A Dogma in Doubt: Hydrolysis of Equatorial Ligands of PtIV Complexes under Physiological Conditions
Kastner A., Poetsch I., Mayr J., Burda J.V., Roller A., Heffeter P., Keppler B.K., Kowol C.R.
Angewandte Chemie - International Edition, 2019
10.
Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
Fronik P., Poetsch I., Kastner A., Mendrina T., Hager S., Hohenwallner K., Schueffl H., Herndler-Brandstetter D., Koellensperger G., Rampler E., Kopecka J., Riganti C., Berger W., Keppler B.K., Heffeter P., et. al.
Journal of Medicinal Chemistry, 2021
12.
Intracellular Processing of Riboflavin in Human Breast Cancer Cells
Bareford L.M., Phelps M.A., Foraker A.B., Swaan P.W.
Molecular Pharmaceutics, 2008
14.
Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
Huang J., Ding W., Zhu X., Li B., Zeng F., Wu K., Wu X., Wang F.
Frontiers in Chemistry, 2022
16.
Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
Spector D., Pavlov K., Beloglazkina E., Krasnovskaya O.
International Journal of Molecular Sciences, 2022
18.
Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug
Krasnovskaya O.O., Akasov R.A., Spector D.V., Pavlov K.G., Bubley A.A., Kuzmin V.A., Kostyukov A.A., Khaydukov E.V., Lopatukhina E.V., Semkina A.S., Vlasova K.Y., Sypalov S.A., Erofeev A.S., Gorelkin P.V., Vaneev A.N., et. al.
ACS applied materials & interfaces, 2023
19.
Development of a novel radiofluorinated riboflavin probe for riboflavin receptor-targeting PET imaging
Li J., Valkenburgh J.V., Fang J., Zhang D., Chen Y., Chen Q., Jia G., Chen A.Z., Zhang X., Chen K.
Pharmacological Research, 2022
21.
Recent advances of platinum‐based anticancer complexes in combinational multimodal therapy
Zhong T., Yu J., Pan Y., Zhang N., Qi Y., Huang Y.
Advanced healthcare materials, 2023
22.
Platinum(IV)-based prodrugs as an alternative to Pt(II)-based drugs: synthesis and biological action
Spector Daniil V., Bubley Anna A., Beloglazkina Elena K., Krasnovskaya Olga O.
Russian Chemical Reviews, 2023
23.
NIR-dye bridged human serum albumin reassemblies for effective photothermal therapy of tumor
Shi Z., Luo M., Huang Q., Ding C., Wang W., Wu Y., Luo J., Lin C., Chen T., Zeng X., Mei L., Zhao Y., Chen H.
Nature Communications, 2023
25.
BODIPY: synthesis, modification, and applications in sensing and biomedicine
Spector Daniil, Abramchuk D. S., Bykusov V. V., Zharova A. O., Egorova E. S., Voskresenskaya A. S., Olovyanishnikov A. R., Kuzmichev I. A., Bubley A. A., Antipin R. L., Beloglazkina Elena, Krasnovskaya Olga
Russian Chemical Reviews, 2024
26.
Bortnevskaya Y.S., Malikova V.A., Karpechenko N.Y., Bragina N.A., Zhdanova K.A.
Mendeleev Communications, 2024